Ovid Therapeutics Inc.
Ovid Therapeutics Inc.
Your view on OVID
Overview
What the company does, where it operates, and who runs it.
About Ovid Therapeutics Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir,
- Headquarters
- 1460 Broadway, New York City, NY, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir,
- Headquarters
- 1460 Broadway, New York City, NY, US
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States.
The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies.
It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H.
Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Ovid Therapeutics Inc., and the rating behind it. OVID last traded at $2.69; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Ovid Therapeutics Inc.. Starting points for Ovid Therapeutics Inc.: EPS -$0.47, beta 0.25 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Ovid Therapeutics Inc.. Ovid Therapeutics Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Ovid Therapeutics Inc.. Trailing twelve-month EPS for Ovid Therapeutics Inc. stands at -$0.47. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Ovid Therapeutics Inc.. Ovid Therapeutics Inc. has reported as a listed company since 2017. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Ovid Therapeutics Inc. valued side by side against its closest peers. Ovid Therapeutics Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Ovid Therapeutics Inc., and how their positions are changing. At a $502.1M market value, institutional positions materially move Ovid Therapeutics Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Ovid Therapeutics Inc. executives and directors. Shares of Ovid Therapeutics Inc. have traded between $0.24 and $2.01 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Ovid Therapeutics Inc.. Ovid Therapeutics Inc. is a $502.1M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Ovid Therapeutics Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Ovid Therapeutics Inc.. Coverage tracks Ovid Therapeutics Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.